News
ICCC
5.38
-0.74%
-0.04
*ImmuCell: Announces Initiation of Investigational Pdt Use of Cattle Infection Treatment Re-Tain
Dow Jones · 1d ago
*ImmuCell: Intends to Use Opportunity to Test Market Acceptance of Pdt >ICCC
Dow Jones · 1d ago
*ImmuCell: Opportunity Is Not Expected to Generate Significant Rev or Profit >ICCC
Dow Jones · 1d ago
ImmuCell Announces Initiation of Investigational Product Use of Re-Tain®
Barchart · 1d ago
Weekly Report: what happened at ICCC last week (0324-0328)?
Weekly Report · 3d ago
IMMUCELL CORPORATION FORM 10-K
Press release · 6d ago
Weekly Report: what happened at ICCC last week (0317-0321)?
Weekly Report · 03/24 11:10
Weekly Report: what happened at ICCC last week (0310-0314)?
Weekly Report · 03/17 11:20
Weekly Report: what happened at ICCC last week (0303-0307)?
Weekly Report · 03/10 11:22
Weekly Report: what happened at ICCC last week (0224-0228)?
Weekly Report · 03/03 11:21
ImmuCell Posts Y/Y Q4 Earnings Growth, Awaits FDA Approval for Re-Tain
Barchart · 02/28 13:00
ImmuCell’s Earnings Call Highlights Robust Recovery
TipRanks · 02/28 00:57
ImmuCell Reports Strong Sales Growth and Recovery
TipRanks · 02/27 04:14
ImmuCell Q4 EPS $0.06 Up From $(0.15) YoY, Sales $7.75M Up From $5.10M YoY
Benzinga · 02/25 21:10
IMMUCELL CORPORATION FY NET INCOME USD -2.157 MILLION
Reuters · 02/25 21:05
IMMUCELL CORP -QTRLY SHR LOSS $0.06
Reuters · 02/25 21:05
*Immucell 4Q Net $515,000 >ICCC
Dow Jones · 02/25 21:05
Press Release: ImmuCell Announces Unaudited -2-
Dow Jones · 02/25 21:05
Press Release: ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2024
Dow Jones · 02/25 21:05
ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2024
Barchart · 02/25 15:05
More
Webull provides a variety of real-time ICCC stock news. You can receive the latest news about Immucell through multiple platforms. This information may help you make smarter investment decisions.
About ICCC
More
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing Immediate Immunity against each of the three causes of calf scours (E. coli, coronavirus, and rotavirus).